Clinical Trial Update: A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study assessing safety, tolerability, immunogenicity, and bioactivity of DE-122 injectable solution for refractory exudative age-related macular dege…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• DE-122

Snippet

Sponsor: Santen Inc. | Conditions: Age-Related Macular Degeneration | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-01-14